GALLI, MATTEO
 Distribuzione geografica
Continente #
NA - Nord America 467
EU - Europa 253
AS - Asia 199
SA - Sud America 47
AF - Africa 39
Totale 1.005
Nazione #
US - Stati Uniti d'America 457
RU - Federazione Russa 149
SG - Singapore 133
IT - Italia 44
BR - Brasile 42
CI - Costa d'Avorio 34
CN - Cina 29
IE - Irlanda 16
VN - Vietnam 11
GB - Regno Unito 8
CA - Canada 7
IN - India 6
DE - Germania 5
FI - Finlandia 5
HK - Hong Kong 5
NL - Olanda 5
PL - Polonia 5
BD - Bangladesh 4
CZ - Repubblica Ceca 4
JP - Giappone 4
SE - Svezia 4
AR - Argentina 3
ES - Italia 3
MX - Messico 3
SN - Senegal 3
CH - Svizzera 2
ZA - Sudafrica 2
AT - Austria 1
CO - Colombia 1
EC - Ecuador 1
GR - Grecia 1
IQ - Iraq 1
IR - Iran 1
JO - Giordania 1
MY - Malesia 1
SA - Arabia Saudita 1
TR - Turchia 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 1.005
Città #
Dallas 126
Singapore 96
Santa Clara 92
Moscow 86
Abidjan 34
Ashburn 31
Los Angeles 31
Beijing 16
Dublin 16
Chandler 14
Chicago 13
Rende 12
New York 11
Buffalo 8
Boston 6
Civitanova Marche 6
Reggio Emilia 6
São Paulo 6
Boardman 5
Brooklyn 5
Ho Chi Minh City 5
Hong Kong 5
Montreal 5
Orem 5
Cambridge 4
Lawrence 4
San Francisco 4
Stockholm 4
Tokyo 4
Warsaw 4
Andover 3
Catania 3
Dakar 3
Jacksonville 3
Poplar 3
Tremestieri Etneo 3
Turku 3
Atlanta 2
Bastiglia 2
Bismarck 2
Chennai 2
Columbus 2
Denver 2
Des Moines 2
Guarujá 2
Hanoi 2
Johannesburg 2
Kochi 2
Nuremberg 2
Rome 2
Scarsdale 2
Alvorada 1
Amman 1
Amsterdam 1
Ankara 1
Arcoverde 1
Arraial do Cabo 1
Arroio Grande 1
Belo Horizonte 1
Bernareggio 1
Boa Esperança 1
Bofete 1
Bologna 1
Boydton 1
Brasília 1
Bremen 1
Bắc Giang 1
Cajazeiras 1
Castanhal 1
Cleveland 1
Cranston 1
Curitiba 1
Da Nang 1
Dhaka 1
Embu das Artes 1
Glasgow 1
Gravina di Catania 1
Greenville 1
Guaratinguetá 1
Gustavo Adolfo Madero 1
Haiphong 1
Hebei 1
Helena 1
Helsinki 1
Houston 1
Ipirá 1
Itapetinga 1
Itapevi 1
Jacundá 1
Jeddah 1
Jiaxing 1
Joinville 1
José C. Paz 1
João Pessoa 1
Kuala Lumpur 1
Lappeenranta 1
London 1
Macapá 1
Madre de Deus 1
Manchester 1
Totale 762
Nome #
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 133
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 98
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial 89
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 86
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 77
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 76
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 68
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 65
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis 59
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 54
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 52
Weight gain: A possible side effect of all antiretrovirals 48
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 43
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 42
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 36
Totale 1.026
Categoria #
all - tutte 3.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.381


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 6 0 3 0 1 0
2021/202218 1 3 0 0 3 0 3 1 1 0 0 6
2022/202351 4 2 2 5 5 7 0 8 14 0 1 3
2023/202422 1 8 1 0 0 3 0 1 0 0 8 0
2024/2025295 0 22 9 7 98 43 9 5 18 28 34 22
2025/2026623 45 30 147 84 152 165 0 0 0 0 0 0
Totale 1.026